

Enfortumab vedotin-ejfv (ADC)

Summary

Catalog No.	DHJ41099
Alternative Names	Padcev, ASG-22ME
Clone ID	Enfortumab vedotin-ejfv
Species reactivity	Human
Form	Liquid
Concentration	1 mg/ml
Purity	>90% as determined by SEC.
Clonality	Monoclonal
Applications	Research Grade Biosimilar
Target	LNIR, NECTIN4, PRR4 receptor-related protein 4, Nectin cell adhesion molecule 4, Ig superfamily receptor LNIR, Nectin-4, PVRL4
Purification	Purified by Ion Exchange Chromatography.
Endotoxin level	Please contact with the lab for this information.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Note	For research use only. Not suitable for clinical or therapeutic use.

Description

Enfortumab vedotin-ejfv is an ADC consisting of a Nectin-4-directed antibody and Monomethyl auristatin E (MMAE) , suitable for adult patients with locally advanced or metastatic urothelial carcinoma, or who have received programmed cell death protein 1 (PD-1) inhibitor or programmed cell death ligand 1 (PD-L1) inhibitor therapy or neoadjuvant/adjuvant platinum-based chemotherapy for locally advanced or metastatic cancer.

Data Image
